It is hard to overstate what almost happened in the last few days: a three-judge panel on the U.S. Court of Appeals for the Fifth Circuit accepted Louisiana’s request for an injunction that would have halted telehealth dispensing of mifepristone nationwide, even in states where abortion remains legal.
Two days later, the Supreme Court pressed pause, temporarily. Circuit Justice Samuel Alito entered an administrative stay keeping the Fifth Circuit’s order from taking effect through 5 p.m. ET on May 11.
That is the headline. The civics lesson is the part we do not talk about enough: who, exactly, has the power to shut down access to a drug across the entire country by court order, and what legal levers make that kind of nationwide whiplash possible.
Join the Discussion
What this fight is about
The immediate dispute centers on the FDA’s 2023 change to the safety program governing mifepristone, known as a REMS. The FDA removed the in-person dispensing requirement, which opened the door for broader telehealth prescribing and mailing of the medication.
Louisiana’s attorney general, Liz Murrill, is challenging that FDA decision in federal court. Earlier this year, she asked the courts to impose an injunction against telehealth abortion care while that lawsuit continues.
The Fifth Circuit panel’s move to freeze telehealth dispensing nationwide would have functioned like a sudden national restriction, not by Congress passing a law, but by a court order that would have effectively rolled back the FDA’s 2023 change while litigation proceeds.
Two manufacturers, Danco Laboratories and GenBioPro, filed an emergency request at the Supreme Court to stop the Fifth Circuit order from snapping into effect. Alito’s stay did just that, at least for now.
What an administrative stay does
An administrative stay is the judiciary’s pause button. It is not a final decision on who wins. It is a way to preserve the status quo while the Court decides whether a longer stay is warranted and how quickly to move.
In practical terms, the stay means the FDA’s current 2023 REMS framework remains in effect during the pause. That matters because the moment the stay disappears, the Fifth Circuit’s order can spring back to life unless the Supreme Court, or the Fifth Circuit itself, changes course.
Who can make it “nationwide”
The Constitution does not assign a single official the power to declare a nationwide rule about abortion pills. This authority emerges from the structure of federal courts and the kinds of remedies judges can issue.
1) A federal district judge can bind a federal agency
Federal trial courts can enjoin federal agencies. If the defendant is the FDA and the court orders the FDA to do or not do something, the practical impact is often national because the FDA operates nationally.
This is how cases that begin with one set of plaintiffs can generate nationwide effects. It is not that the judge is legislating for all 50 states. It is that the judge is controlling a federal actor whose policies apply everywhere.
2) A circuit panel can make that order bite immediately
Once an order is appealed, the circuit court can affirm it, reverse it, or put it on hold. In this situation, a three-judge panel of the Fifth Circuit took a step that would have made the injunction operative.
Because the target is an FDA rule, not a single clinic, the footprint of the order is effectively the whole country.
3) The Supreme Court can pause it fast, even through one Justice
Emergency applications frequently go first to a single Justice assigned to that circuit. Here, Alito acted as Circuit Justice to enter a short-term administrative stay. That single act prevented the Fifth Circuit’s order from taking effect immediately.
But do not mistake speed for finality. The Supreme Court can extend a stay, modify it, or lift it. And it can do so with minimal explanation, because emergency orders often arrive without the full briefing and argument of a merits case.
Why this felt like a ban
When people hear abortion ban, they usually picture a legislature criminalizing a procedure. This episode shows another route: litigation that targets the federal regulatory pipeline.
If mailed mifepristone is cut off, access collapses not just where abortion is banned, but also in states where it remains lawful, because providers and pharmacies are forced back into a narrower dispensing framework.
This is also why telehealth has become such a major fault line. Telehealth abortions accounted for nearly 27% of abortions in the first half of 2025, and at least 91,000 abortions in all of 2025. When a remedy hits telehealth, it is not nibbling at the edges. It is reaching into a major channel of access.
Why providers are alarmed
The stay is a relief, but it is not stability. Clinics, telehealth providers, and patients are looking at a calendar where access can tighten overnight depending on what happens next.
That is why Julie Burkhart of Wellspring Health Access described the stakes in plain terms: All people should be able to reliably obtain essential reproductive health care, including abortion care, without interference from judges or politicians.
She added: Americans deserve better than to have their right to the full spectrum of health care options taken away or restored on a whim.
Elisa Wells, co-founder of Plan C, also pointed to the safety record and the fear created by the litigation itself: Of course, we are relieved that the stay allows telehealth providers to continue to mail abortion pills, which we know from more than 100 studies are very safe, whether prescribed in a clinic or by telehealth,
she said. But we remain concerned about the final outcome of this case, which bases its claims on bogus claims about mifepristone’s safety.
Nationwide injunctions and stress tests
There is a deeper constitutional question sitting underneath the medication and the FDA paperwork: should a single district judge or a single appellate panel be able to bind the federal government nationwide, especially on an issue as politically combustive as abortion?
Supporters of broad injunctions say they are necessary to prevent the federal government from applying an unlawful policy to anyone. Critics argue they encourage judge-shopping and create national policy swings based on which courthouse a case is filed in.
Either way, the mechanism is now a central feature of American governance. We are living in a system where national rules are increasingly made, unmade, and temporarily paused through emergency litigation.
What happens before May 11
May 11 is not just a date on a calendar. It is a deadline built into the Supreme Court’s temporary order.
- If the Supreme Court extends the stay, the FDA’s 2023 telehealth-friendly framework remains in place longer while the Court considers the case.
- If the Supreme Court lifts the stay, the Fifth Circuit order can take effect, and telehealth mailing of mifepristone could be halted nationwide.
- If the Supreme Court replaces the stay with a different remedy, it could allow some access while restricting other parts, depending on how it frames the FDA’s authority and the plaintiffs’ requested relief.
The bottom line
In constitutional terms, this fight is not just about abortion. It is about the modern administrative state and the courts that supervise it.
Congress wrote statutes that give the FDA authority to regulate drugs. The FDA used that authority to adjust the REMS for mifepristone. A state attorney general asked a federal court to block that adjustment. A federal appellate panel agreed, briefly. And one Justice of the Supreme Court pressed pause long enough for the full Court to decide what to do next.
No one voted on a national telehealth abortion policy. But for a moment, a court order came close to creating one. The stay means the order is blocked, for now. The constitutional question is whether our system is comfortable letting nationwide access to medication hinge on emergency motions, injunctions, and the calendar of a single court.